Anthropic's Claude Science Wants to Run Drug Discovery, Not Just Help With It
Finn's Take· TL;DR- Claude Science autonomously runs drug discovery tasks end-to-end, not just assisting—screening compounds and analyzing data independently from high-level instructions.
- Platform consolidates 60+ scientific functions across genomics, proteomics, and cheminformatics into one workbench, eliminating constant tool-switching for researchers.
- Anthropic launching its own drug discovery program targeting neglected diseases while courting pharma partnerships amid $965 billion valuation and upcoming IPO.
A New Kind of AI Lab Partner
Anthropic's bold claim with its new Claude Science platform is that it goes beyond merely assisting scientists — it can actually do their work. "Claude can run the work — not help with it, not accelerate it — even run it," said Zubair Jandali, who leads Anthropic's healthcare and life sciences commercial team, at a launch event held on June 30 in San Francisco.
Anthropic introduced Claude Science as a dedicated AI workbench designed to give scientists a unified environment for computational research, eliminating the need to constantly switch between databases, pipelines, and tools. The app — currently in beta testing — allows researchers to use a single research environment to work with dozens of databases, file formats, and analysis tools at "all stages of their work," according to Anthropic.
Claude Science comes with more than 60 functions catering to areas like genomics, structural biology, proteomics, and cheminformatics, which can assist researchers in performing a broad range of tasks like CRISPR screen design, single-cell RNA sequencing analysis, and 3D protein structure rendering. Researchers can give the platform a single instruction, like asking it to screen for a promising drug compound, and it will carry out the analysis, run the necessary computing tasks, and return results on its own.
What Makes This Different From Earlier AI Tools
Claude Science is a major new product intended to support scientific research in the same way that Claude Code supports software engineering. Like Claude Code, it can autonomously carry out meaningful work when given concise, high-level instructions, and it has access to tools that make it particularly useful for research in computational biology and drug development.
Claude Science is not a new AI model. Anthropic is explicit on this point: "It runs the same Claude models already available to everyone today (including Claude Opus 4.8), with no special access and no gating." It can also run on a lab's own infrastructure rather than sending data to Anthropic's servers, a meaningful feature for institutions handling sensitive or proprietary research data.
Early users are already reporting significant time savings. Allen Institute neuroscientist Jérôme Lecoq used the tool to build a multi-agent computational review pipeline. At the UCSF Brain Tumor Center, Stephen Francis's group relied on Claude Science to accelerate germline analysis of glioma, compressing a process that previously took considerably longer into a fraction of the time, with results independently validated.
The Stakes: Drug Discovery, IPOs, and Neglected Diseases
The launch of Claude Science arrives at a pivotal moment for Anthropic. The announcement is one of the company's most ambitious moves in the healthcare world — a sector it has increasingly courted as it looks to diversify revenue beyond coding tools. The stakes are especially high as Anthropic prepares for its much-anticipated initial public offering. In May, Anthropic closed a $65 billion Series H funding round, bringing its valuation to $965 billion.
The tightening bond between tech and pharma comes as the latter sector increasingly takes an "all in on AI" approach, with the total value of AI partnerships in the space taking a 120% uptick year-on-year between 2024 and 2025, according to GlobalData's Pharmaceutical Intelligence Center. Novartis CEO Vas Narasimhan, who also sits on Anthropic's board, broke the drug development timeline into three types of delay — information, operational, and biological — and believes AI is already collapsing the first two.
As Anthropic explores the promise of the life sciences sector, it is also firing up an internal drug discovery program of its own, which will focus on discovering treatments for "neglected" diseases. Anthropic's life sciences head Eric Kauderer-Abrams explained the reasoning: "We believe in the power of tight feedback loops, and there's no substitute for having our own experiences alongside you all in the trenches trying to develop drugs." Whether Claude Science can truly compress the notoriously slow, billion-dollar drug development pipeline remains to be proven — but the pharmaceutical world is clearly paying close attention.